The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Fibroblast Growth Factor 21 Corrects Obesity in Mice
Abstract
Fibroblast growth factor 21 (FGF21) is a metabolic regulator that provides efficient and durable glycemic and lipid control in various animal models. However, its potential to treat obesity, a major health concern affecting over 30% of the population, has not been fully explored. Here we report that systemic administration of FGF21 for 2 wk in diet-induced obese and ob/ob mice lowered their mean body weight by 20% predominantly via a reduction in adiposity. Although no decrease in total caloric intake or effect on physical activity was observed, FGF21-treated animals exhibited increased energy expenditure, fat utilization, and lipid excretion, reduced hepatosteatosis, and ameliorated glycemia. Transcriptional and blood cytokine profiling studies revealed effects consistent with the ability of FGF21 to ameliorate insulin and leptin resistance, enhance fat oxidation and suppress de novo lipogenesis in liver as well as to activate futile cycling in adipose. Overall, these data suggest that FGF21 exhibits the therapeutic characteristics necessary for an effective treatment of obesity and fatty liver disease and provides novel insights into the metabolic determinants of these activities.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“prolonged administration of FGF21 or FGF21 analogues has important metabolic effects, including a marked decrease in body weight in rodents and non-human primates, and more modest effects on body weight in humans3,40,58,77,78.”
From Metabolic messengers: FGF21 (2021) · cites this paper as [77]
In the citing paper
“Pharmacological administration of FGF21 to obese rodents reverses diabetes and obesity through increasing energy expenditure77,78.”
From Metabolic messengers: FGF21 (2021) · cites this paper as [77]
In the citing paper
“Pharmacological administration of FGF21 decreases plasma glucose and lipid levels, improves insulin and leptin sensitivity, decreases hepatic steatosis, increases energy expenditure [[131], [132], [133], [134], [135], [136]], and decreases sugar and alcohol intake in mice [[137], [138], [139], [140], [141], [142]].”
From Hepatokines and metabolism: Deciphering communication from the liver (2021) · cites this paper as [131]
In the citing paper
“Pharmacological administration of FGF21 decreases plasma glucose and lipid levels, improves insulin and leptin sensitivity, decreases hepatic steatosis, increases energy expenditure [[131], [132], [133], [134], [135], [136]], and decreases sugar and alcohol intake in mice [[137], [138], [139], [140], [141], [142]].”
From Hepatokines and metabolism: Deciphering communication from the liver (2021) · cites this paper as [131]
In the citing paper
“Pharmacological administration of FGF21 decreases plasma glucose and lipid levels, improves insulin and leptin sensitivity, decreases hepatic steatosis, increases energy expenditure [[131], [132], [133], [134], [135], [136]], and decreases sugar and alcohol intake in mice [[137], [138], [139], [140], [141], [142]].”
From Hepatokines and metabolism: Deciphering communication from the liver (2021) · cites this paper as [131]
In the citing paper
“Pharmacological administration of FGF21 decreases plasma glucose and lipid levels, improves insulin and leptin sensitivity, decreases hepatic steatosis, increases energy expenditure [[131], [132], [133], [134], [135], [136]], and decreases sugar and alcohol intake in mice [[137], [138], [139], [140], [141], [142]].”
From Hepatokines and metabolism: Deciphering communication from the liver (2021) · cites this paper as [131]
In the citing paper
“A myriad of studies ensued demonstrating that administering FGF21 to obese or diabetic rodents and primates markedly reduced body weight and significantly improved carbohydrate and lipid homeostasis (21, 64, 65, 141).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [21]
In the citing paper
“When administered to diabetic and obese animal models, FGF21 provides multiple metabolic benefits and has been shown to decrease blood glucose levels and body weight, improve insulin and leptin sensitivity, improve plasma lipid profiles, and decrease hepatic steatosis (21, 64, 141, 142).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [21]
In the citing paper
“Importantly, in animal models FGF21 treatment not only prevents (64) but also reverses diabetes and obesity (21, 141).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [21]
In the citing paper
“Since FGF21 administration increases energy expenditure and the browning of adipose tissues in vivo (21, 64, 141), it was hypothesized that FGF21 regulates adaptive thermogenesis in response to cold.”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [21]
In the citing paper
“It is clear that FGF21 treatment elicits significant metabolic changes in many tissues, including the liver and adipose tissues (21, 141).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [21]
In the citing paper
“FGF21’s ability to reduce body weight, glucose levels, and lipid concentrations in models of obesity generated substantial initial interest”
From FGF21 and the physiological regulation of macronutrient preference (2020) · cites this paper as [116]
Citations
Cites
Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation
Watanabe, M., Houten, S. M., Mataki, C., Christoffolete, M. A., Kim, B. W., Sato, H., Messaddeq, N., Harney, J. W., Ezaki, O., Kodama, T., et al. (2006) · Nature · doi:10.1038/nature04330 · Cited by 2,220
FGF-21 as a novel metabolic regulator
Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23606 · Cited by 2,125
Self-citationCellular signaling by fibroblast growth factor receptors
Eswarakumar, V. P., Lax, I., & Schlessinger, J. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.001 · Cited by 1,923
Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li, Y., Goetz, R., Mohammadi, M., Esser, V., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.003 · Cited by 1,504
Badman, M. K., Pissios, P., Kennedy, A. R., Koukos, G., Flier, J. S., & Maratos-Flier, E. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.002 · Cited by 1,495
Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young
Fajans, S. S., Bell, G. I., & Polonsky, K. S. (2001) · New England Journal of Medicine · doi:10.1056/nejmra002168 · Cited by 1,123
Handschin, C., & Spiegelman, B. M. (2006) · Endocrine Reviews · doi:10.1210/er.2006-0037 · Cited by 1,090
New drug targets for type 2 diabetes and the metabolic syndrome
Moller, D. E. (2001) · Nature · doi:10.1038/414821a · Cited by 1,012
Self-citationIdentification of a novel FGF, FGF-21, preferentially expressed in the liver
Nishimura, T., Nakatake, Y., Konishi, M., & Itoh, N. (2000) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(00)00067-1 · Cited by 847
Role for Stearoyl-CoA Desaturase-1 in Leptin-Mediated Weight Loss
Cohen, P., Miyazaki, M., Socci, N. D., Hagge-Greenberg, A., Liedtke, W., Soukas, A. A., Sharma, R., Hudgins, L. C., Ntambi, J. M., & Friedman, J. M. (2002) · Science · doi:10.1126/science.1071527 · Cited by 826
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 995
Frayling, T. M., Beaumont, R. N., Jones, S. E., Yaghootkar, H., Tuke, M. A., Ruth, K. S., Casanova, F., West, B., Locke, J., Sharp, S., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.070 · Cited by 101
Lee, J. H., Kang, Y. E., Chang, J. Y., Park, K. C., Kim, H.-W., Kim, J. T., Kim, H. J., Yi, H., Shong, M., Chung, H. K., et al. (2016) · PubMed Central · Cited by 101
FGF21 regulates hepatic metabolic pathways to improve steatosis and inflammation
Keinicke, H., Sun, G., Mentzel, C. M. J., Fredholm, M., John, L. M., Andersen, B., Raun, K., & Gerstenberg, M. K. (2020) · Endocrine Connections · doi:10.1530/ec-20-0152 · Cited by 104
Li, Y., Wong, K., Walsh, K. X., Gao, B., & Zang, M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.429852 · Cited by 101
Perrone, C. E., Mattocks, D. A. L., Plummer, J. D., Chittur, S. V., Mohney, R. P., Vignola, K. S., Orentreich, D. S., & Orentreich∥, N. (2012) · Lifestyle Genomics · doi:10.1159/000339347 · Cited by 100
Fibroblast growth factor 21 night watch: advances and uncertainties in the field
Kharitonenkov, A., & DiMarchi, R. D. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12580 · Cited by 97
Self-citationFibroblast growth factor 21 is a sensitive biomarker of mitochondrial disease
Davis, R. L., Liang, C., Edema‐Hildebrand, F., Riley, C., Needham, M., & Sue, C. M. (2013) · Neurology · doi:10.1212/01.wnl.0000436068.43384.ef · Cited by 102
FGF21 and the physiological regulation of macronutrient preference
Hill, C. M., Qualls-Creekmore, E., Berthoud, H.-R., Soto, P., Yu, S., McDougal, D. H., Münzberg, H., & Morrison, C. D. (2020) · Endocrinology · doi:10.1210/endocr/bqaa019 · Cited by 99
Uebanso, T., Taketani, Y., Yamamoto, H., Amo, K., Ominami, H., Arai, H., Takei, Y., Masuda, M., Tanimura, A., Harada, N., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022976 · Cited by 99
Hill, C. M., Laeger, T., Albarado, D. C., McDougal, D. H., Berthoud, H.-R., Münzberg, H., & Morrison, C. D. (2017) · Scientific Reports · doi:10.1038/s41598-017-07498-w · Cited by 97
Nuclear receptors linking metabolism, inflammation, and fibrosis in nonalcoholic fatty liver disease
Puengel, T., Liu, H., Guillot, A., Heymann, F., Tacke, F., & Peiseler, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052668 · Cited by 95
Sánchez, J., Palou, A., & Picó, C. (2009) · Endocrinology · doi:10.1210/en.2009-0466 · Cited by 98
Kim, E., Lee, S., Jhun, J. Y., Byun, J. K., Jeong, J. H., Lee, S.-Y., Kim, J. K., Choi, J. Y., & Cho, M. (2016) · Mediators of Inflammation · doi:10.1155/2016/5813030 · Cited by 101
Leng, Y., Wang, Z., Tsai, L.-K., Leeds, P. R., Fessler, E. B., Wang, J., & Chuang, D. M. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.192 · Cited by 96
Impaired Mitochondrial Fat Oxidation Induces FGF21 in Muscle
Vandanmagsar, B., Warfel, J. D., Wicks, S. E., Ghosh, S., Salbaum, J. M., Burk, D., Dubuisson, O. S., Mendoza, T. M., Zhang, J., Noland, R. C., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.057 · Cited by 92
Cold and Exercise: Therapeutic Tools to Activate Brown Adipose Tissue and Combat Obesity
da Silva, C. P. V., Hernández‐Saavedra, D., White, J. D., & Stanford, K. (2019) · Biology · doi:10.3390/biology8010009 · Cited by 102
Henriksson, E., & Andersen, B. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.601349 · Cited by 97
Baruch, A., Wong, C., Chinn, L. W., Vaze, A., Sonoda, J., Gelzleichter, T., Chen, S., Lewin-Koh, N., Morrow, L., Dheerendra, S., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2012073117 · Cited by 95
Liver Derived FGF21 Maintains Core Body Temperature During Acute Cold Exposure
Ameka, M., Markan, K. R., Morgan, D. A., BonDurant, L. D., Idiga, S. O., Naber, M. C., Zhu, Z., Zingman, L. V., Grobe, J. L., Rahmouni, K., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-37198-y · Cited by 93
Emerging role of fibroblast growth factors 15/19 and 21 as metabolic integrators in the liver
Cicione, C., Degirolamo, C., & Moschetta, A. (2012) · Hepatology · doi:10.1002/hep.25929 · Cited by 95
Role of adipose tissue in methionine–choline-deficient model of non-alcoholic steatohepatitis (NASH)
Jha, P., Knopf, A., Köfeler, H. C., Mueller, M., Lackner, C., Höefler, G., Claudel, T., & Trauner, M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.02.012 · Cited by 99
Jiang, Y. Z., Rose, A. J., Sijmonsma, T., Bröer, A., Pfenninger, A., Herzig, S., Schmoll, D., & Bröer, S. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.02.003 · Cited by 96
Fibroblast growth factor 21 is a metabolic regulator that plays a role in the adaptation to ketosis
Domouzoglou, E. M., & Maratos–Flier, E. (2011) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.110.001941 · Cited by 93
The Structural Biology of the FGF19 Subfamily
Beenken, A., & Mohammadi, M. (2012) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4614-0887-1_1 · Cited by 93
FGF21 in obesity and cancer: New insights
Lu, W., Li, X., & Luo, Y. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.11.026 · Cited by 93
Adipokines and the Endocrine Role of Adipose Tissues
Giralt, M., Cereijo, R., & Villarroya, F. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_6 · Cited by 97
FGF21: a novel prospect for the treatment of metabolic diseases.
Kharitonenkov, A., & Shanafelt, A. B. (2009) · PubMed · Cited by 91
Self-citationTeijeiro, A., Garrido, A., Ferré, A., Perna, C., & Djouder, N. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00371-1 · Cited by 91
Regulation of metabolic health by essential dietary amino acids
Green, C. L., & Lamming, D. W. (2018) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2018.07.004 · Cited by 91
PPARγ and PPARα synergize to induce robust browning of white fat in vivo
Kroon, T., Harms, M., Maurer, S., Bonnet, L., Alexandersson, I., Lindblom, A., Ahnmark, A., Nilsson, D., Gennemark, P., O’Mahony, G., et al. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.02.007 · Cited by 92
The role of the retinoid receptor, RAR/RXR heterodimer, in liver physiology
Li, B., Cai, S., & Boyer, J. L. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166085 · Cited by 92
Hypothalamic control of seasonal changes in food intake and body weight
Ebling, F. J. P. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2014.10.003 · Cited by 88
Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice
Wu, X., Ge, H., Lemon, B. D., Weiszmann, J., Gupte, J., Hawkins, N., Li, X., Tang, J., Lindberg, R. A., & Li, Y. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907812106 · Cited by 88
Bielohuby, M., Menhofer, D., Kirchner, H., Stoehr, B. J. M., Müller, T. D., Stock, P., Hempel, M., Stemmer, K., Pfluger, P. T., Kienzle, E., et al. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00478.2010 · Cited by 94
Fibroblast Growth Factor 21 and the Adaptive Response to Nutritional Challenges
Martínez‐Garza, Ú., Torres‐Oteros, D., Yarritu, A., Marrero, P. F., Haro, D., & Relat, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194692 · Cited by 88
Mechanisms Linking Metabolic-Associated Fatty Liver Disease (MAFLD) to Cardiovascular Disease
Badmus, O. O., Hinds, T. D., & Stec, D. E. (2023) · Current Hypertension Reports · doi:10.1007/s11906-023-01242-8 · Cited by 90
Marino, J. S., Stechschulte, L. A., Stec, D. E., Nestor‐Kalinoski, A. L., Coleman, S., & Hinds, T. D. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.752311 · Cited by 87
Hepatokines and non-alcoholic fatty liver disease
Lebensztejn, D. M., Flisiak-Jackiewicz, M., Białokoz-Kalinowska, I., Bobrus-Chociej, A., & Kowalska, I. (2016) · Acta Biochimica Polonica · doi:10.18388/abp.2016_1252 · Cited by 90
Fibroblast Growth Factor 21 As an Emerging Therapeutic Target for Type 2 Diabetes Mellitus
So, W. Y., & Leung, P. S. (2016) · Medicinal Research Reviews · doi:10.1002/med.21390 · Cited by 85
Liu, J., Yang, K., Yang, J., Xiao, W., Le, Y., Yu, F., Gu, L., Lang, S., Tian, Q., Jin, T., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.02.037 · Cited by 85
Keipert, S., Kutschke, M., Lamp, D., Brachthäuser, L., Neff, F., Meyer, C. W., Oelkrug, R., Kharitonenkov, A., & Jastroch, M. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.04.006 · Cited by 85
Self-citationSphingolipid metabolism in non-alcoholic fatty liver diseases
Régnier, M., Polizzi, A., Guillou, H., & Loiseau, N. (2018) · Biochimie · doi:10.1016/j.biochi.2018.07.021 · Cited by 88
Lee, Y., Lim, S. K., Hong, E. S., Kim, J. H., Moon, M. K., Chun, E. J., Choi, S. I., Kim, Y., Park, Y. J., Park, K. S., et al. (2012) · Clinical Endocrinology · doi:10.1111/cen.12134 · Cited by 84
Lawan, A., Zhang, L., Gatzke, F., Min, K., Jurczak, M. J., Al‐Mutairi, M., Richter, P., Camporez, J. P., Couvillon, A. D., Pesta, D. H., et al. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00503-14 · Cited by 88
Diabetes mellitus: new challenges and innovative therapies
Sena, C. M., Bento, C. F., Pereira, P., & Seiça, R. M. F. (2010) · The EPMA Journal · doi:10.1007/s13167-010-0010-9 · Cited by 92
Liu, C., Schönke, M., Zhou, E., Li, Z., Kooijman, S., Boon, M. R., Larsson, M., Wallenius, K., Dekker, N., Barlind, L., et al. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab076 · Cited by 81
Imaging of Brown Adipose Tissue: State of the Art
Sampath, S. C., Sampath, S. C., Bredella, M. A., Cypess, A. M., & Torriani, M. (2016) · Radiology · doi:10.1148/radiol.2016150390 · Cited by 83
Endogenous FGF21-signaling controls paradoxical obesity resistance of UCP1-deficient mice
Keipert, S., Lutter, D., Schroeder, B. O., Brandt, D., Ståhlman, M., Schwarzmayr, T., Graf, E., Fuchs, H., de Angelis, M. H., Tschöp, M. H., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14069-2 · Cited by 84
FGF19 and FGF21: In NASH we trust
Talukdar, S., & Kharitonenkov, A. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101152 · Cited by 82
Self-citationPerspectives for feed-efficient animal production1
Niemann, H., Kuhla, B., & Flachowsky, G. (2011) · Journal of Animal Science · doi:10.2527/jas.2011-4235 · Cited by 82
Mitochondrial uncoupling and longevity – A role for mitokines?
Klaus, S., & Ost, M. (2019) · Experimental Gerontology · doi:10.1016/j.exger.2019.110796 · Cited by 80
Cyphert, H. A., Alonge, K. M., Ippagunta, S. M., & Hillgartner, F. B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094996 · Cited by 80
Stein, S., Stepan, H., Kratzsch, J., Verlohren, M., Verlohren, H.-J., Drynda, K., Lössner, U., Blüher, M., Stümvoll, M., & Faßhauer, M. (2009) · Metabolism · doi:10.1016/j.metabol.2009.07.003 · Cited by 81
Brown adipose tissue: a potential target in the fight against obesity and the metabolic syndrome
Poekes, L., Lanthier, N., & Leclercq, I. A. (2015) · Clinical Science · doi:10.1042/cs20150339 · Cited by 83
Schibler, U. (2009) · Journal of Biological Rhythms · doi:10.1177/0748730408329383 · Cited by 78
Serum levels of fibroblast growth factor‐21 are increased in chronic and acute renal dysfunction
Hindricks, J., Ebert, T., Bachmann, A., Kralisch, S., Lössner, U., Kratzsch, J., Stolzenburg, J., Dietel, A., Beige, J., Anders, M. S., et al. (2013) · Clinical Endocrinology · doi:10.1111/cen.12380 · Cited by 80
Lee, M. S., Choi, S., Ha, E. S., An, S.-Y., Kim, T. H., Han, S. J., Kim, H. J., Kim, D. J., KANG, Y. Y., & Lee, K. W. (2012) · Metabolism · doi:10.1016/j.metabol.2012.01.012 · Cited by 80
Fibroblast activation protein (FAP) as a novel metabolic target
Sanchez-Garrido, M. A., Habegger, K. M., Clemmensen, C., Holleman, C. L., Müller, T. D., Pérez–Tilve, D., Li, P., Agrawal, A., Finan, B., Drucker, D. J., et al. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.07.003 · Cited by 79
Self-citationSo, W. Y., Cheng, Q., Xu, A., Lam, K. S. L., & Leung, P. S. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.80 · Cited by 79
Muscle mitochondrial stress adaptation operates independently of endogenous FGF21 action
Ost, M., Coleman, V., Voigt, A., van Schothorst, E. M., Keipert, S., van der Stelt, I., Ringel, S., Graja, A., Ambrosi, T., Kipp, A. P., et al. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2015.11.002 · Cited by 75
FGF21-Mediated Improvements in Glucose Clearance Require Uncoupling Protein 1
Kwon, M. M., O’Dwyer, S. M., Baker, R. K., Covey, S. D., & Kieffer, T. J. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.10.021 · Cited by 77
The Neuroendocrine Basis of Anorexia Nervosa and Its Impact on Bone Metabolism
Misra, M., & Klibanski, A. (2011) · Neuroendocrinology · doi:10.1159/000323771 · Cited by 81
Araki, M., Nakagawa, Y., Oishi, A., Han, S., Wang, Y., Kumagai, K., Ohno, H., Mizunoe, Y., IWASAKI, H. O., Sekiya, M., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19072148 · Cited by 82
Omar, B. A., Andersen, B., Hald, J., Raun, K., Nishimura, E., & Åhrén, B. (2013) · Diabetes · doi:10.2337/db13-0710 · Cited by 76
Pharmacological strategies for targeting BAT thermogenesis
Whittle, A. J., Relat, J., & Vidal‐Puig, A. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.04.004 · Cited by 82
Impact of Lipotoxicity on Tissue “Cross Talk” and Metabolic Regulation
Montgomery, M. K., Nardo, W. D., & Watt, M. J. (2019) · Physiology · doi:10.1152/physiol.00037.2018 · Cited by 82
Pathophysiology of NASH in endocrine diseases
Gariani, K., & Jornayvaz, F. R. (2021) · Endocrine Connections · doi:10.1530/ec-20-0490 · Cited by 77
FGF21 reverses MASH through coordinated actions on the CNS and liver
Rose, J. P., Morgan, D. A., Sullivan, A. I., Fu, X., Inigo-Vollmer, M., Burgess, S. C., Meyerholz, D. K., Rahmouni, K., & Potthoff, M. J. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.04.014 · Cited by 75
Fibroblast growth factor 21 is not required for the antidiabetic actions of the thiazoladinediones
Adams, A. C., Coşkun, T., Cheng, C., O’Farrell, L. S., DuBois, S. L., & Kharitonenkov, A. (2013) · Molecular Metabolism · doi:10.1016/j.molmet.2013.05.005 · Cited by 75
Self-citationXiao, J., Bei, Y., Liu, J., Dimitrova‐Shumkovska, J., Kuang, D., Zhou, Q., Li, J., Yang, Y., Xiang, Y., Wang, F., et al. (2015) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12733 · Cited by 75
Plasma FGF21 displays a circadian rhythm during a 72‐h fast in healthy female volunteers
Andersen, B., Beck‐Nielsen, H., & Højlund, K. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04084.x · Cited by 74
Berti, L., Irmler, M., Zdichavsky, M., Meile, T., Böhm, A., Stefan, N., Fritsche, A., Beckers, J., Königsrainer, A., Häring, H.-U., et al. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.04.002 · Cited by 73
Fibroblast growth factor 21, the endocrine FGF pathway and novel treatments for metabolic syndrome
Zhang, J., & Li, Y. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.10.021 · Cited by 73
The potential function and clinical application of FGF21 in metabolic diseases
Chen, Z., Yang, L., Liu, Y., Huang, P., Song, H., & Zheng, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1089214 · Cited by 73
Obesity and Pancreatic Cancer: Insight into Mechanisms
Eibl, G., & Rozengurt, E. (2021) · Cancers · doi:10.3390/cancers13205067 · Cited by 76
Combined Serum Biomarkers in Non-Invasive Diagnosis of Non-Alcoholic Steatohepatitis
Yang, M., Xu, D., Liu, Y., Guo, X., Li, W., Guo, C., Zhang, H., Gao, Y., Mao, Y., & Zhao, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131664 · Cited by 72
Samms, R. J., Cheng, C. C., Kharitonenkov, A., Gimeno, R. E., & Adams, A. C. (2016) · Endocrinology · doi:10.1210/en.2015-1722 · Cited by 76
Self-citationFGF21 Is a Hormonal Mediator of the Human “Thrifty” Metabolic Phenotype
Vinales, K. L., Begaye, B., Bogardus, C., Walter, M. F., Krakoff, J. A., & Piaggi, P. (2018) · Diabetes · doi:10.2337/db18-0696 · Cited by 72
Xu, L. L., Huang, D., Hu, Q., Wu, J., Wang, Y., & Feng, J. (2015) · British Journal Of Nutrition · doi:10.1017/s0007114515001130 · Cited by 75
Multi-omics profiling: the way toward precision medicine in metabolic diseases
Hu, C., & Jia, W. (2021) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjab051 · Cited by 75
Self-citationParacrine FGFs target skeletal muscle to exert potent anti-hyperglycemic effects
Lei, Y., Wang, L., Guo, K., Hou, Y., Li, N., Wang, S., Liu, X., Zhao, Q., Zhou, J., Zhao, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27584-y · Cited by 74
Jin, L., Yang, R., Geng, L., & Xu, A. (2023) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-032322-093904 · Cited by 71
FGF21 ameliorates nonalcoholic fatty liver disease by inducing autophagy
Zhu, S., Wu, Y., Ye, X., Ma, L., Qi, J., Yu, D., Wei, Y., Lin, G., Ren, G., & Li, D. (2016) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-016-2774-2 · Cited by 71
Babaknejad, N., Nayeri, H., Hemmati, R., Bahrami, S., & Esmaillzadeh, A. (2018) · Hormone and Metabolic Research · doi:10.1055/a-0623-2909 · Cited by 70
Spann, R. A., Morrison, C. D., & den Hartigh, L. J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.802541 · Cited by 76
Fibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders
Zhang, J., & Li, Y. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00168 · Cited by 70
Goto, T., Hirata, M., Aoki, Y., Iwase, M., Takahashi, H., Kim, M., Li, Y., Jheng, H., Nomura, W., Takahashi, N., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.767590 · Cited by 72
Ribas, F., Villarroya, J., Hondares, E., Giralt, M., & Villarroya, F. (2014) · Biochemical Journal · doi:10.1042/bj20140403 · Cited by 69
Rader, D. J., Maratos-Flier, E., Nguyen, A., Hom, D., Ferriere, M., Li, Y., Kompa, J., Martic, M., Hinder, M., Basson, C. T., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab624 · Cited by 72
Association of Adipose Tissue and Adipokines with Development of Obesity-Induced Liver Cancer
Rajesh, Y., & Sarkar, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042163 · Cited by 75
Nygaard, E., Møller, C. L., Kievit, P., Grove, K. L., & Andersen, B. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.79 · Cited by 69
Fibroblast growth factor 21: a novel metabolic regulator from pharmacology to physiology
Li, H., Zhang, J., & Jia, W. (2013) · Frontiers of Medicine · doi:10.1007/s11684-013-0244-8 · Cited by 67
An, S.-Y., Lee, M. S., Yi, S., Ha, E. S., Han, S. J., Kim, H. J., Kim, D. J., & Lee, K. W. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.01.004 · Cited by 69
Kruse, R., Vienberg, S. G., Vind, B. F., Andersen, B., & Højlund, K. (2017) · Diabetologia · doi:10.1007/s00125-017-4373-5 · Cited by 69
Homeostatic sensing of dietary protein restriction: a case for FGF21
Hill, C. M., Berthoud, H.-R., Münzberg, H., & Morrison, C. D. (2018) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2018.06.002 · Cited by 68
Biomarkers of mitochondrial disorders
Shayota, B. J. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00325 · Cited by 82
Harris, L.-A. L. S., Skinner, J. R., Shew, T. M., Pietka, T., Abumrad, N. A., & Wolins, N. E. (2015) · Diabetes · doi:10.2337/db14-1035 · Cited by 70
FGF21 resistance is not mediated by downregulation of beta-klotho expression in white adipose tissue
Markan, K. R., Naber, M. C., Small, S. M., Peltekian, L., Kessler, R. L., & Potthoff, M. J. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.03.009 · Cited by 70
Maida, A., Chan, J. S. K., Sjøberg, K. A., Zota, A., Schmoll, D., Kiens, B., Herzig, S., & Rose, A. J. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.06.009 · Cited by 68
Dai, H., Hu, W., Zhang, L., Jiang, F., Mao, X., Yang, G., & Li, L. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03588-w · Cited by 65
Metadata
- Authors
- Coskun, T., Bina, H. A., Schneider, M. A., Dunbar, J. D., Hu, C. C., Chen, Y., Moller, D. E., & Kharitonenkov, A.
- Affiliations
- Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285
- Eli Lilly (United States) (US)
- Corresponding author
- Kharitonenkov, Alexei
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2008-08-07
- Volume
- 149
- Issue
- 12
- Pages
- 6018-6027
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2114650931
- Cited by
- 1,031
- References
- 26
- Citations by year
- 2026: 17 · 2025: 34 · 2024: 58 · 2023: 63 · 2022: 57 · 2021: 72 · 2020: 67 · 2019: 76 · 2018: 72 · 2017: 64 · 2016: 78 · 2015: 85 · 2014: 71 · 2013: 62 · 2012: 61
- FWCI
- 12.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- FGF21, obesity, diet-induced obesity, ob/ob mice, energy expenditure, fat oxidation, de novo lipogenesis, hepatic steatosis, insulin resistance, leptin resistance, glycemia, lipid excretion, adipose tissue, metabolic therapy
- MeSH terms
- Animals, Body Weight, Energy Intake, Dietary Fats, Energy Metabolism, Fibroblast Growth Factors, Insulin, Insulin Resistance, Male, Mice, Inbred C57BL, Motor Activity, Obesity, Leptin, Adiposity, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
